CimetrA / Argent BioPharma - LARVOL DELTA

Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P2b | N=240 | Completed | Sponsor: MGC Pharmaceuticals d.o.o | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • IL12A • IL6

Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P2b | N=240 | Recruiting | Sponsor: MGC Pharmaceuticals d.o.o | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2022 ➔ Mar 2023 | Initiation date: Sep 2021 ➔ Oct 2022 | Trial primary completion date: Dec 2021 ➔ Jan 2023

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • IFNG • IL12A • IL1B • IL6 • TNFA

Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P3 | N=252 | Active, not recruiting | Sponsor: MGC Pharmaceuticals d.o.o | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Apr 2023 | Trial primary completion date: Dec 2021 ➔ Feb 2023

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • IFNG • IL1B • IL6 • TNFA

Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P2b; N=240; Not yet recruiting; Sponsor: MGC Pharmaceuticals d.o.o

Clinical • New P2b trial • Infectious Disease • Novel Coronavirus Disease • IFNG • IL12A • IL1B • IL6 • TNFA

Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P3; N=252; Recruiting; Sponsor: MGC Pharmaceuticals d.o.o; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • IFNG • IL1B • IL6 • TNFA

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P2; N=50; Completed; Sponsor: MGC Pharmaceuticals d.o.o; Recruiting ➔ Completed

Clinical • Trial completion • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them. (PubMed, Cochrane Database Syst Rev) - "We identified 16 ongoing studies (including 14 RCTs), which aim to enrol nearly 1250 participants. The interventions included in these trials are ArtemiC (artemisinin, curcumin, frankincense and vitamin C), Citrox (a bioflavonoid), cetylpyridinium chloride, chlorhexidine, chlorine dioxide, essential oils, hydrogen peroxide, hypertonic saline, Kerecis spray (omega 3 viruxide - containing neem oil and St John's wort), neem extract, nitric oxide releasing solution, povidone iodine and saline with baby shampoo.  AUTHORS' We identified no studies for inclusion in this review. Very few interventions have large and dramatic effect sizes. If a positive treatment effect is demonstrated when studies are available for inclusion in this review, it may not be large. In these circumstances in particular it may be a challenge to..."

Clinical • Journal • Review • Allergy • Immunology • Infectious Disease • Novel Coronavirus Disease

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 (clinicaltrials.gov) - P2; N=50; Recruiting; Sponsor: MGC Pharmaceuticals d.o.o; Trial completion date: Jul 2020 ➔ Jan 2021; Trial primary completion date: Jul 2020 ➔ Nov 2020

Clinical • Trial completion date • Trial primary completion date • Immune Modulation • Infectious Disease • Novel Coronavirus Disease

MGC Pharmaceuticals interim results of ArtemiC in Phase II trial on COVID-19 infected patients meet all primary objectives (Proactiveinvestors) - P2, N=50; NCT04382040; Sponsor: MGC Pharmaceuticals d.o.o; "The Phase II double-blind, placebo-controlled clinical trial has met all the primary objectives, with all 10 patients showing significant improvement. Shares jumped 43% on release of the news to A$0.037 and are up from A$0.021 at the market close on July 31....The statistically proven results show two important clinical outcomes: A significant improvement in the clinical parameters of patients in the treatment group; and; No adverse events occurred, demonstrating the safety of the treatment."

Cytokine storm • P2 data • Stock price • Infectious Disease • Novel Coronavirus Disease